Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19209867 | ANTI-CD8 ALPHA DEPLETING ANTIBODIES | May 2025 | September 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18927301 | PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGENASE I and COLLAGENASE II | October 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18914010 | CHIMERIC PROTEIN COMPRISING AN ANTI-INFLUENZA VIRUS ANTIBODY MOIETY AND A MUCOADHESIVE PEPTIDE FRAGMENT FOR PREVENTING OR TREATING INFLUENZA INFECTIONS | October 2024 | September 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18909225 | METHODS OF TREATING OR PREVENTING A CARDIOVASCULAR SYSTEM COMPLICATION OF SICKLE CELL DISEASE WITH AN ANTI-G-CSFR ANTIBODY | October 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18830877 | ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTS | September 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18817109 | ANTI-IL-18BP ANTIBODIES | August 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18773461 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | July 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18771877 | GRP78-BINDING ANTIBODIES AND USE THEREOF IN DETECTING OR NEUTRALIZING GRP78 | July 2024 | November 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18750581 | METHODS FOR TREATMENT OF PSORIASIS WITH AN ANTI-OXLDL ANTIBODY | June 2024 | January 2026 | Allow | 19 | 1 | 0 | No | No |
| 18739702 | NUCLEIC ACIDS ENCODING MODIFIED IMMUNOGLOBULIN FC REGIONS | June 2024 | August 2025 | Allow | 14 | 1 | 1 | No | No |
| 18632662 | ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | April 2024 | July 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18615520 | NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE I AND METHODS OF PRODUCING THE SAME | March 2024 | June 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18593002 | METHODS FOR TREATING PULMONARY DISEASE WITH A LIGAND BINDING DOMAIN OF A TGF-BETA TYPE II RECEPTOR | March 2024 | March 2026 | Allow | 25 | 3 | 1 | No | No |
| 18441998 | METHODS OF TREATMENT OR PREVENTION OF IMMUNE RESPONSES AND INFLAMMATORY DISEASES WITH ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES | February 2024 | May 2025 | Allow | 15 | 1 | 1 | No | No |
| 18439331 | NME INHIBITORS AND METHODS OF USING NME INHIBITORS | February 2024 | September 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18439510 | METHOD OF TREATING AN IMMUNE-RELATED DISORDER OR DISEASE ASSOCIATED WITH AN ORGAN OR TISSUE TRANSPLANT WITH A COMBINATION OF AN ANTI-CD2 ANTIBODY AND A CTLA-4 CO-STIMULATION BLOCKADE | February 2024 | July 2025 | Abandon | 17 | 2 | 1 | No | No |
| 18431294 | Methods of Treating Myopathies with Anti-Pro/Latent Myostatin Antibodies | February 2024 | February 2026 | Allow | 25 | 2 | 1 | No | No |
| 18413753 | AMELIORATION AND TREATMENT OF INFARCTION DAMAGE WITH A POLYPEPTIDE SEGEMENT OF BNIP3 | January 2024 | February 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18396301 | METHODS OF TREATMENT OF CANCER WITH ANTIBODY-IL-2 ENGRAFTED PROTEINS | December 2023 | December 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18390569 | METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLS | December 2023 | April 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18505590 | METHOD OF ASSESSING REGULATION OF AN IMMUNE RESPONSE TO AN ADMINISTERED AGENT BY MEASURING ACTIVATION OF NODOSE GANGLION NEURONS | November 2023 | May 2025 | Allow | 19 | 3 | 1 | No | No |
| 18379847 | METHODS OF TREATING ISCHEMIA- OR REPERFUSION-INJURY WITH AN ANTIBODY INHIBITOR OF INTEGRIN ALPHA9 | October 2023 | October 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18459465 | PROPERDIN BINDING PROTEIN AND USE THEREOF | September 2023 | August 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18453691 | Antagonistic CD40 Monoclonal Antibodies and Uses Thereof | August 2023 | May 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18235550 | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | August 2023 | December 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18357639 | METHOD OF TREATING DIABETES WITH FGF21 AND GLP1 DOUBLE GENE-MODIFIED CELL | July 2023 | June 2025 | Allow | 22 | 2 | 1 | No | No |
| 18346205 | HETERODIMERIC RELAXIN FUSIONS AND USES THEREOF | July 2023 | August 2024 | Allow | 14 | 0 | 0 | No | No |
| 18329308 | NUCLEIC ACIDS ENCODING CLOSTRIDIUM HISTOLYTICUM DELTA TOXIN AND METHODS OF PRODUCING THE SAME | June 2023 | May 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18200117 | METHODS FOR TREATMENT OF ACCELERATED ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS WITH AN ANTI-APO B100 ANTIBODY | May 2023 | July 2025 | Allow | 26 | 2 | 1 | No | No |
| 18311557 | CMV VACCINE AND METHOD OF MAKING AND USING THE SAME | May 2023 | September 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18140121 | METHODS OF TREATING IRON OVERLOAD WITH A BMP INHIBITOR | April 2023 | June 2025 | Allow | 26 | 1 | 1 | No | No |
| 18301924 | Anti-CD30 and Anti-CD3 Bispecific Antibodies and Methods of Immunotherapy for CD30+ Malignancies | April 2023 | April 2025 | Allow | 24 | 1 | 1 | No | No |
| 18193393 | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY | March 2023 | November 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18193581 | NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE | March 2023 | April 2025 | Allow | 25 | 0 | 1 | Yes | No |
| 18125353 | APLNR Modulators and Uses Thereof | March 2023 | December 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18163667 | ANTI-CD30 ANTIBODIES | February 2023 | February 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18103194 | METHODS OF INHIBITING THE T CELL RECEPTOR BY ADMINISTERING A MONOCLONAL ANTIBODY THAT BINDS TRBV9 | January 2023 | September 2025 | Allow | 31 | 1 | 1 | No | No |
| 18159556 | CELL PRIMED WITH CTGF-D4 AND INSULIN OR IGF-1 AND USE IN METHODS FOR CARDIAC TISSUE REPAIR | January 2023 | July 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18156617 | ANTIBODY ENDOHEDRAL METALLOFULLERENE CONJUGATE AND USES THEREOF | January 2023 | June 2025 | Abandon | 29 | 4 | 1 | Yes | No |
| 18012089 | METHOD OF TREATING AN IMMUNE-RELATED DISORDER OR DISEASE ASSOCIATED WITH AN ORGAN OR TISSUE TRANSPLANT WITH A COMBINATION OF AN ANTI-CD2 ANTIBODY AND A CTLA-4 CO-STIMULATION BLOCKADE | December 2022 | February 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 18063981 | METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN | December 2022 | October 2025 | Allow | 34 | 3 | 1 | Yes | No |
| 17937073 | METHODS OF TREATING IMMUNE-MEDIATED PULMONARY INJURY WITH AN ANTI-ILT7 ANTIBODY | September 2022 | February 2026 | Allow | 40 | 1 | 1 | No | No |
| 17946916 | NUCLEIC ACIDS ENCODING SWITCH RECEPTORS USING IL-9 RECEPTOR SIGNALING DOMAINS | September 2022 | September 2024 | Allow | 24 | 2 | 1 | No | No |
| 17933055 | METHODS OF TREATMENT OF ARTHRITIS AND/OR PSORIASIS WITH PHARMACEUTICAL FORMULATIONS OF ETANERCEPT | September 2022 | September 2024 | Allow | 24 | 1 | 1 | No | No |
| 17893515 | LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME | August 2022 | July 2025 | Allow | 35 | 1 | 1 | No | No |
| 17819630 | Combination of Retromer Pharmacological Chaperones and Exogenous Retromer for the Treatment of Alzheimer's Disease and Other Neurodegenerative Diseases and Disorders | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17819327 | ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF A FIBROTIC CONDITION | August 2022 | March 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17881413 | KIT FOR PREPARING DISEASE-TREATING AGENT, DISEASE-TREATING AGENT AND METHOD FOR PREPARING DISEASE-TREATING AGENT | August 2022 | December 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17814221 | Method of Making Anti-Pro/Latent Myostatin Antibodies | July 2022 | December 2024 | Allow | 29 | 2 | 1 | No | No |
| 17866188 | METHOD FOR REDUCING AN IMMUNE RESPONSE OF POLYPEPTIDE-FC CONJUGATE | July 2022 | March 2026 | Abandon | 44 | 2 | 1 | No | No |
| 17859130 | METHOD OF USING NAP-2 AND TGF-alpha TO IMPROVE CARDIAC FUNCTION | July 2022 | March 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 17810423 | C-KIT ANTIBODIES AND METHOD FOR TREATING CANCER WITH SUCH | July 2022 | August 2024 | Allow | 25 | 1 | 1 | No | No |
| 17838863 | T-CELL REACTIVITY PLATFORM | June 2022 | November 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17837943 | GRP78-BINDING ANTIBODIES AND USES THEREOF IN DETECTING OR NEUTRALIZING GRP78 | June 2022 | August 2024 | Allow | 26 | 1 | 1 | No | No |
| 17836473 | NUCLEIC ACIDS ENCODING CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | June 2022 | September 2024 | Allow | 28 | 1 | 1 | No | No |
| 17827100 | Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injury | May 2022 | February 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17780398 | TEIPP PEPTIDE VARIANT AND USE AS A MEDICAMENT | May 2022 | September 2025 | Allow | 40 | 1 | 1 | No | No |
| 17777335 | NANOVACCINE FOR HEART FAILURE | May 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17776337 | HUMAN HENDRA VIRUS AND NIPAH VIRUS ANTIBODIES AND METHODS OF USE THEREFOR | May 2022 | October 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17725142 | ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES | April 2022 | October 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17718087 | IL-12 HETERODIMERIC FC-FUSION PROTEINS | April 2022 | August 2024 | Allow | 28 | 2 | 1 | No | No |
| 17765514 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS | March 2022 | December 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17764142 | METHODS FOR TREATING MYELOFIBROSIS AND RELATED CONDITIONS | March 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17764143 | METHODS FOR TREATING ANEMIA OF CHRONIC DISEASE | March 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17763925 | COMBINATION THERAPY WITH CGRP ANTAGONISTS | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17703747 | ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENT IN CARDIOVASCULAR DISEASE | March 2022 | November 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17761088 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE THEREOF | March 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17694295 | USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS TO INDICATE PREVENTION OF CARDIOVASCULAR DISEASE WITH A STATIN | March 2022 | May 2025 | Allow | 38 | 2 | 0 | No | No |
| 17642837 | IMMUNOGENIC PEPTIDE FRAGMENTS OF METALLOPROTEASE ADAMTS-7 AND USES THEREOF IN ANTI-ATHEROSCLEROSIS AND RELATED DISEASES | March 2022 | December 2025 | Allow | 45 | 2 | 1 | No | No |
| 17666921 | NOVEL ANTI-TROPONIN T ANTIBODIES | February 2022 | October 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17633131 | ANTI-HOG TCN1 MONOCLONAL ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF | February 2022 | September 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17630474 | METHODS OF ADMINISTERING ANTI-SIGLEC-8 ANTIBODIES AND CORTICOSTEROIDS | January 2022 | February 2026 | Abandon | 48 | 0 | 1 | No | No |
| 17579355 | METHODS OF DIAGNOSING, DETERMINING THE PROGRESSION OF, AND TREATING A PROSTATE CANCER | January 2022 | September 2024 | Allow | 32 | 2 | 1 | No | No |
| 17627089 | FUSION PROTEIN OF ANTI-ETA ANTIBODY AND TGF-BETA TRAP AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF IN METHOD OF TREATMENT | January 2022 | July 2025 | Allow | 42 | 1 | 1 | No | No |
| 17626755 | ANTI-8-HYDROXY-2'-DEOXYGUANOSINE ANTIBODY OR ANTIBODY FRAGMENT THEREOF, PRODUCTION METHOD, KIT, MEASURING METHOD, AND DEVICE FOR MEASUREMENT | January 2022 | March 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17626679 | METHODS FOR TREATING CEREBRAL VASOSPASM WITH A PD-1 AGONIST | January 2022 | January 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17560022 | CHIMERIC RECEPTOR COMPRISING A LIGAND BINDING DOMAIN AND AN ENDODOMAIN COMPRISING A CYTOKINE RECEPTOR ENDODOMAIN AND AN INTRACELLULAR T CELL SIGNALLING DOMAIN | December 2021 | January 2026 | Allow | 48 | 3 | 1 | Yes | No |
| 17645211 | NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN | December 2021 | November 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17551098 | METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR | December 2021 | January 2026 | Abandon | 49 | 0 | 1 | No | No |
| 17615900 | METHODS OF TREATING FULMINANT VIRAL HEPATITIS WITH AN IL-18 ANTAGONIST IN A PATIENT WITH AN IL-18BP VARIANT | December 2021 | September 2025 | Allow | 46 | 1 | 1 | No | No |
| 17504116 | ENGINEERED OSTEOCALCINS FOR TREATING SARCOPENIA | October 2021 | March 2026 | Allow | 53 | 2 | 1 | Yes | No |
| 17486820 | HUMAN APOB100 EPITOPES, METHODS AND USES FOR MODULATING INFLAMMATORY RESPONSES, AND TREATING ADVERSE CARDIOVASCULAR EVENTS, DISEASE AND ATHEROSCLEROSIS | September 2021 | June 2025 | Allow | 45 | 3 | 1 | Yes | No |
| 17448389 | METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION | September 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17405124 | METHODS OF USING FLT3L-Fc FUSION PROTEINS FOR THE TREATMENT OF DISEASES | August 2021 | December 2024 | Abandon | 40 | 2 | 2 | No | No |
| 17423549 | THERAPEUTIC NANOCONJUGATES COMPRISING STEFIN A AND USES THEREOF | July 2021 | October 2025 | Allow | 51 | 1 | 1 | No | No |
| 17359211 | TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR | June 2021 | September 2024 | Allow | 39 | 2 | 1 | No | No |
| 17239983 | METHOD FOR TREATING FIBROSIS WITH AN ANTI-GDF-15 ANTIBODY | April 2021 | March 2025 | Allow | 47 | 4 | 1 | No | No |
| 17202790 | Methods of Treatment with Anti-PACAP Antibodies | March 2021 | August 2024 | Allow | 41 | 2 | 1 | No | Yes |
| 17271767 | METHOD TO ASSESS CAR FUNCTIONALITY | February 2021 | December 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17271441 | METHODS FOR TREATING NON-SMALL LUNG CANCER AND FOR PREPARING A SAMPLE | February 2021 | August 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17150457 | METHODS OF ADMINISTERING MESENCHYMAL STEM CELLS ACTIVATED BY CYTOKINES FOR ENHANCING IMMUNOSUPPRESSION | January 2021 | August 2024 | Allow | 43 | 2 | 1 | No | No |
| 17256553 | ANTI-CD6 ANTIBODY-GROWTH FACTOR COMPLEX FOR TREATING AUTOIMMUNE DISEASES | December 2020 | March 2025 | Allow | 50 | 2 | 1 | No | No |
| 17250259 | POZIOTINIB COMBINATIONS WITH AN ANTI-HER1, HER2 OR HER4 ANTIBODY AND METHODS OF USE THEREOF | December 2020 | January 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17077433 | METHOD FOR TREATING PULMONARY HYPERTENSION WITH ANTIBODIES TO HUMAN RESISTIN | October 2020 | October 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16979471 | NUCLEIC ACIDS ENCODING IL-13 RECEPTOR ALPHA 2 (IL13RA2) CHIMERIC ANTIGEN RECEPTOR FOR TUMOR SPECIFIC T CELL IMMUNOTHERAPY | September 2020 | July 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 16987237 | ANTI-ASGR-1 MONOCLONAL INHIBITORY ANTIBODIES | August 2020 | March 2024 | Allow | 43 | 4 | 1 | No | No |
| 16964785 | METHODS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN AN ORGAN WITH ANTIBODY ANTAGONISTS OF IL-33 | July 2020 | July 2024 | Allow | 48 | 6 | 1 | No | No |
| 16964720 | CHIMERIC PROTEIN COMPRISING ANTI-XCR1 ANTIBODY AND MODIFIED INTERFERON ALPHA 2 | July 2020 | February 2026 | Allow | 60 | 6 | 1 | Yes | No |
| 16772260 | Cell Comprising a Chimeric Antigen Receptor or a Transgenic T-Cell Receptor and Comprising a Chimeric TNF Receptor | June 2020 | February 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 16753216 | TRANSTHYRETIN IMMUNOGLOBULIN FUSIONS | April 2020 | December 2024 | Allow | 56 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HOWARD, ZACHARY C.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 30.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HOWARD, ZACHARY C works in Art Unit 1674 and has examined 158 patent applications in our dataset. With an allowance rate of 93.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner HOWARD, ZACHARY C's allowance rate of 93.7% places them in the 81% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by HOWARD, ZACHARY C receive 2.32 office actions before reaching final disposition. This places the examiner in the 65% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HOWARD, ZACHARY C is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +9.5% benefit to allowance rate for applications examined by HOWARD, ZACHARY C. This interview benefit is in the 42% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 30.3% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 60.5% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 95.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 76.9% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 25.3% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.1% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.